PharmaFocus Today – Page 153 – media

drugdu

The amyotrophic lateral sclerosis (ALS) market across the 8MM (8MM: the US, France, Germany, Italy, Spain, the UK, Japan, and Canada) is projected to grow at a compound annual growth rate (CAGR) of 15 per cent from $317 million in 2019 to $1.28 billion in 2029, forecasts drugdu. The key opinion leaders (KOLs) interviewed by drugdu identified the greatest unmet needs within the ALS space. These entail earlier diagnosis, disease-modifying therapies (DMTs), identification of biomarkers, and efficacious first-line treatment options. However, the consensus amongst them is that the need to diagnose ALS early and the development of DMTs is imperative for any change to take place within the treatment space. Momna Ali, Healthcare Analyst at drugdu, comments, “Due to the variety in the presentation of ALS development and symptoms, there have been historical difficulties in diagnosing patients in a timely manner. Pharmaceutical companies have an opportunity to educate physicians both ...
- Source: drugdu
- 200
- June 15, 2024
IIIT-Delhi’S AMRSense secure second prize at Trinity Challenge on AMR

The Trinity Challenge has announced the winners of its second competition (the Trinity Challenge on Antimicrobial Resistance), aimed at tackling the escalating threat of antimicrobial resistance (AMR). The awarded projects focus on addressing critical data gaps in communities and lower-income countries, which are disproportionately impacted by antibiotic-resistant infections. IIIT-Delhi announces that the project “AMRSense: Empowering Communities with a Proactive One Health Ecosystem,” led by Prof Tavpritesh Sethi in collaboration with CHRI-PATH, 1mg.com, and ICMR, has secured the joint second prize. The project shares this honor with “OASIS: OneHealth Antimicrobial Stewardship for Informal Health Systems,” also from India. Each joint second prize winner will receive £600,000 in funding over the next three years. All winners will also benefit from ongoing post-award innovation and scaling support. AMRSense addresses the challenges of engaging, motivating, and training community health workers (CHWs) in AMR surveillance and management, compounded by the lack of a comprehensive data ...
- Source: drugdu
- 238
- June 15, 2024
First-Line PSA Testing More Cost-Effective Than First-Line MRI for Prostate Cancer Screening

Current prostate cancer (PCa) screening protocols typically begin with prostate-specific antigen (PSA) testing, which, if elevated, may lead to further assessment using multiparametric magnetic resonance imaging (mpMRI). Now, a cost-effectiveness analysis has revealed that using biparametric magnetic resonance imaging (bpMRI) as an initial screening tool is less cost-effective than the traditional approach of first-line PSA testing followed by mpMRI. This conclusion held true even when assuming no cost for bpMRI, indicating that the financial savings do not compensate for the drawbacks of using the first-line MRI approach. A team of researchers from Fred Hutchinson Cancer Center (Seattle, WA, USA), in collaboration with other institutions, developed a microsimulation model to compare the effectiveness and cost-efficiency of first-line bpMRI versus first-line PSA with reflex mpMRI for prostate cancer screening. The study showed that initiating screening with MRI significantly increased the incidence of false positives, unnecessary prostate biopsies, and overdiagnoses, without a corresponding ...
- Source: drugdu
- 170
- June 14, 2024
Self-Taught AI Tool Diagnoses and Predicts Severity of Common Lung Cancer

A computer program powered by artificial intelligence (AI) and trained on nearly half a million tissue images can effectively diagnose cases of adenocarcinoma, the most prevalent type of lung cancer. The computer program developed and tested by researchers at NYU Langone Health (New York, NY, USA) provides an unbiased, detailed, and reliable second opinion for patients and oncologists regarding the presence of the cancer and the possibility and timing of its return, also known as its prognosis. This is because the program incorporates structural features of tumors from 452 adenocarcinoma patients, who are among the more than 11,000 patients in the U.S. National Cancer Institute’s Cancer Genome Atlas. Importantly, the program operates independently and is “self-taught,” deciding by itself which structural features are most critical for assessing the severity of the disease and its impact on tumor recurrence. In their research, the algorithm, known as histomorphological phenotype learning (HPL), successfully ...
- Source: drugdu
- 150
- June 14, 2024
FDA Grants Emergency Use Authorization to Roche’s Cobas Liat SARS-CoV-2, Influenza A/B, & RSV Nucleic Acid Test

Don Tracy, Associate Editor The cobas is classified as a four-in-one molecular test that can identify SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus from a single nasopharyngeal or anterior nasal swab sample. The FDA has granted Emergency Use Authorization (EUA) to Roche’s cobas liat SARS-CoV-2, Influenza A/B & respiratory syncytial virus (RSV) nucleic acid test. According to the company, it is a four-in-one molecular test, defined as an automated multiplex RT-PCR assay that can detect SARS-CoV-2, influenza A, influenza B, and RSV from a nasal swab sample. Additionally, Roche reported that full results can be expected in 20 minutes via a compact analyzer.1 “Diagnostics play a critical role in the fight against respiratory illness,” said Matt Sause, CEO, Roche Diagnostics, in a press release. “We are proud to provide this innovative test to address the significant burden placed on healthcare systems. Now, healthcare professionals will be able to ...
- Source: drugdu
- 195
- June 14, 2024
Avidity Bio’s RNA Therapy Flashes Early Signs of Treating a Muscular Dystrophy’s Root Cause

Avidity Biosciences’ RNA therapy for facioscapulohumeral muscular dystrophy has preliminary clinical data showing it knocked down expression of a gene that causes this rare disease. More details will be presented at a medical conference this week. By Frank VinluanAn experimental RNA therapy from Avidity Biosciences has early clinical trial results showing it reduced by half the expression of a gene at the root of a rare, inherited form of muscular dystrophy with no FDA-approved therapies. Furthermore, patients in the study are showing signs of regaining muscle function. Based on these initial results announced Wednesday, Avidity said it plans to accelerate the start of additional cohorts in the Phase 1/2 study that could support an application seeking regulatory approval in this disease, facioscapulohumeral muscular dystrophy (FSHD). More details about the data are coming soon. Avidity plans to present the preliminary results during the Annual FSHD Society International Research Congress meeting, which ...
- Source: drugdu
- 151
- June 14, 2024
LucyTx announces additional $12.5m research funding for neurological diseases

Lucy Therapeutics (LucyTx) has announced it has raised $12.5m in additional funding to develop potentially new drugs and advance the company’s research programmes for neurological diseases. The funding, provided by existing investors, Engine Ventures and Safar Partners, with recent participation from the Bill & Melinda Gates Foundation, the Michael J. Fox Foundation and £1.6m from Parkinson’s UK’s Biotech programme, brings the company’s total funding to $36m. The new project aims to develop novel therapies that are based on mitochondrial small-molecule treatments and diagnostic biomarkers for Alzheimer’s (AD) and Parkinson’s disease (PD), as well as continue the development of a novel drug target for Rett syndrome, a rare genetic neurological and developmental disorder that affects brain development. AD and PD are the two most common neurodegenerative diseases worldwide, affecting around 24 million and ten million people, respectively. Using LucyTx’s platform, the team will analyse a variety of disease drivers central to ...
- Source: drugdu
- 116
- June 14, 2024
US researchers develop AI liquid biopsy test to help identify lung cancer earlier

Researchers from the Johns Hopkins Kimmel Cancer Center and other institutions have developed and validated a liquid biopsy test using artificial intelligence (AI) to help identify lung cancer earlier. The new study published in Cancer Discovery demonstrated that the new blood test could help accelerate lung cancer screening while reducing death rates. Currently the leading cause of global cancer incidence and death worldwide, lung cancer accounts for an estimated two million diagnoses and 1.8 million deaths annually. For the last five years, researchers have developed a test to detect patterns of DNA fragments found in patients with lung cancer. Participants with and without cancer who met the criteria for low-dose computed tomography (CT) were recruited to receive the blood test to determine which patients were most at risk and would benefit from a follow-up CT screening to help overcome issues regarding appointments, such as the time it takes to arrange ...
- Source: drugdu
- 158
- June 14, 2024
Chiatai Tianqing and China Resources Pharmaceutical Commercial signed a strategic cooperation agreement

On June 7, Chiatai Tianqing Pharmaceutical Group and China Resources Pharmaceutical Commercial signed a strategic cooperation agreement in Tianjin. Based on the principle of resource sharing, complementary advantages and common development, the two parties will carry out in-depth cooperation in the fields of pharmaceutical research and development, production, sales and circulation, and jointly help the sustainable development of China’s pharmaceutical industry. Chiatai Tianqing’s commercial director Qi Tianze and CR Pharmaceuticals Commercial Deputy General Manager Dong Hao signed the agreement on behalf of the two parties. As one of the leading pharmaceutical companies in China, Chiatai Tianqing has always been committed to researching and developing innovative drugs, improving drug quality and meeting patients’ needs. With strong R&D strength and market competitiveness, the company has won wide recognition and trust. As an important pillar industry of China Resources Group, China Resources Pharmaceutical Commercial has a comprehensive pharmaceutical distribution network and market channels, ...
- Source: drugdu
- 135
- June 14, 2024
Innovent Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer

SAN FRANCISCO and SUZHOU, China, June 13, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its TOPO1i anti-CLDN18.2 ADC (R&D code: IBI343), for the treatment of advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC) that has relapsed and/or is refractory to one prior line of therapy. Previously, IBI343 has already received FDA approval of its IND application for the treatment of PDAC. At the ASCO 2024 Annual Meeting, Innovent reported the preliminary Phase 1 results of IBI343 in advanced PDAC patients who have received at least one prior line of treatment. In the 6 mg/kg dose group, among the 10 evaluable PDAC patients with CLDN18.2 1/2/3+≥60%, the overall response ...
- Source: drugdu
- 151
- June 14, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.